Complex Immunogenicity Assessment in Caplacizumab-treated Patients with Immune-mediated Thrombotic Thrombocytopenic Purpura Who Have Received Plasma Exchange

Overview

Journal Res Pract Thromb Haemost

Publisher Elsevier

Date 2024 Dec 17

PMID 39687921

Authors

Brendy Van Butsel

Maria Laura Sargentini-Maier

Ana Paula Marques

Yana Vandenbossche

Gabriela Marcheva

Sriya Gunawardena

Samuel Pine

Affiliations

Soon will be listed here.

Abstract

Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab. TPE can complicate antidrug antibody (ADA) measurements by transferring pre-existing antibodies (pre-Abs) into patients via donor plasma and/or diluting treatment-emergent (TE) ADAs.

Objectives: To assess the presence of ADAs in patients with iTTP who received caplacizumab.

Methods: Immunogenicity data from patients with iTTP receiving caplacizumab once daily plus TPE/immunosuppressive therapy in 4 clinical trials (TITAN, HERCULES, Post-HERCULES, and a trial conducted in Japanese patients) in the clinical development program were analyzed. ADA and modified ADA assays differentiated pre-Abs from TE ADAs. A functional neutralizing antibody (NAb) assay and a neutralizing epitope characterization assay (NECA) assessed the presence of ADAs with neutralizing potential. The impact of ADAs on efficacy, pharmacokinetics/pharmacodynamics, and safety was evaluated.

Results: Among 228 patients in 4 studies, prevalence of pre-Abs ranged from 17.1% (TITAN) to 56.7% (HERCULES), while TE ADA prevalence ranged from 3.1% (HERCULES) to 14.3% (Japanese study). The TE NAb-positive rate ranged from 0% (Japanese study) to 12% (Post-HERCULES) using the functional NAb assay and from 2.7% (Post- HERCULES) to 14.3% (Japanese study) using the NECA. The presence of these antibodies did not impact treatment efficacy or safety.

Conclusion: A complex immunogenicity assay strategy was required to define the pre-Ab/TE ADA status of patients with iTTP treated with caplacizumab in a clinical trial setting. In addition to the wide range of pre-Abs observed, few patients had detectable TE ADAs or NAbs, neither of which affected efficacy/safety.

References

Duggan S . Caplacizumab: First Global Approval. Drugs. 2018; 78(15):1639-1642. PMC: 6280848. DOI: 10.1007/s40265-018-0989-0. View

Chaturvedi S, Abbas H, McCrae K . Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura. Am J Hematol. 2015; 90(10):E208. PMC: 4579009. DOI: 10.1002/ajh.24138. View

Scully M, Cataland S, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga J . Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019; 380(4):335-346. DOI: 10.1056/NEJMoa1806311. View

Upreti H, Kasmani J, Dane K, Braunstein E, Streiff M, Shanbhag S . Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019; 134(13):1037-1045. PMC: 7022317. DOI: 10.1182/blood.2019001056. View

Ishiwatari-Ogata C, Kyuuma M, Ogata H, Yamakawa M, Iwata K, Ochi M . Ozoralizumab, a Humanized Anti-TNFα NANOBODY Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG. Front Immunol. 2022; 13:853008. PMC: 8902368. DOI: 10.3389/fimmu.2022.853008. View

Jin B, Odongo S, Radwanska M, Magez S . NANOBODIES®: A Review of Diagnostic and Therapeutic Applications. Int J Mol Sci. 2023; 24(6). PMC: 10057852. DOI: 10.3390/ijms24065994. View

Coddens A, Snoeck V, Bontinck L, Buyse M, Pine S . An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics. J Immunol Methods. 2020; 487:112896. DOI: 10.1016/j.jim.2020.112896. View

Joly B, Coppo P, Veyradier A . An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2019; 12(6):383-395. DOI: 10.1080/17474086.2019.1611423. View

Zheng X, Vesely S, Cataland S, Coppo P, Geldziler B, Iorio A . ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18(10):2496-2502. PMC: 8091490. DOI: 10.1111/jth.15010. View

10.

Scully M, Rubia J, Pavenski K, Metjian A, Knobl P, Peyvandi F . Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. J Thromb Haemost. 2022; 20(12):2810-2822. PMC: 9827931. DOI: 10.1111/jth.15892. View

11.

van Brummelen E, Ros W, Wolbink G, Beijnen J, Schellens J . Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. Oncologist. 2016; 21(10):1260-1268. PMC: 5061540. DOI: 10.1634/theoncologist.2016-0061. View

12.

Miyakawa Y, Imada K, Ichikawa S, Uchiyama H, Ueda Y, Yonezawa A . The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. Int J Hematol. 2022; 117(3):366-377. PMC: 9970947. DOI: 10.1007/s12185-022-03495-6. View

13.

Hanlon A, Metjian A . Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Ther Adv Hematol. 2020; 11:2040620720902904. PMC: 7011322. DOI: 10.1177/2040620720902904. View

14.

Kremer Hovinga J, Coppo P, Lammle B, Moake J, Miyata T, Vanhoorelbeke K . Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017; 3:17020. DOI: 10.1038/nrdp.2017.20. View

15.

Peyvandi F, Scully M, Kremer Hovinga J, Cataland S, Knobl P, Wu H . Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016; 374(6):511-22. DOI: 10.1056/NEJMoa1505533. View

16.

Sukumar S, Lammle B, Cataland S . Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021; 10(3). PMC: 7867179. DOI: 10.3390/jcm10030536. View

17.

Kyuuma M, Kaku A, Mishima-Tsumagari C, Ogawa B, Endo M, Tamura Y . Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation. Front Immunol. 2023; 14:1149874. PMC: 10141648. DOI: 10.3389/fimmu.2023.1149874. View